Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Nov 08, 2023

SELL
$31.86 - $67.26 $6.91 Million - $14.6 Million
-216,734 Reduced 37.78%
356,875 $15.5 Million
Q2 2023

Aug 14, 2023

SELL
$31.86 - $67.26 $6.91 Million - $14.6 Million
-216,734 Reduced 37.78%
356,875 $15.5 Million
Q1 2023

Nov 08, 2023

SELL
$45.44 - $74.26 $5.37 Million - $8.77 Million
-118,068 Reduced 17.07%
573,609 $37.7 Million
Q1 2023

May 15, 2023

SELL
$45.44 - $74.26 $5.37 Million - $8.77 Million
-118,068 Reduced 17.07%
573,609 $37.7 Million
Q4 2022

Nov 08, 2023

BUY
$41.39 - $81.0 $13.9 Million - $27.1 Million
334,802 Added 93.81%
691,677 $31.1 Million
Q4 2022

Feb 14, 2023

BUY
$41.39 - $81.0 $28.6 Million - $56 Million
691,677 New
691,677 $31.1 Million
Q4 2021

Feb 14, 2022

SELL
$119.57 - $139.07 $22 Million - $25.6 Million
-184,299 Closed
0 $0
Q3 2021

Nov 08, 2023

BUY
$109.17 - $142.35 $2.31 Million - $3.02 Million
21,185 Added 12.99%
184,299 $24.5 Million
Q3 2021

Nov 15, 2021

BUY
$109.17 - $142.35 $20.1 Million - $26.2 Million
184,299 New
184,299 $24.5 Million
Q2 2021

Aug 16, 2021

SELL
$100.34 - $115.69 $16.4 Million - $18.9 Million
-163,114 Closed
0 $0
Q1 2021

Nov 08, 2023

SELL
$101.51 - $125.27 $11.8 Million - $14.6 Million
-116,389 Reduced 41.64%
163,114 $17.2 Million
Q1 2021

May 13, 2021

SELL
$101.51 - $125.27 $11.8 Million - $14.6 Million
-116,389 Reduced 41.64%
163,114 $17.2 Million
Q4 2020

Nov 08, 2023

SELL
$85.88 - $105.36 $6.64 Million - $8.15 Million
-77,372 Reduced 21.68%
279,503 $29.1 Million
Q4 2020

Feb 16, 2021

BUY
$85.88 - $105.36 $12 Million - $14.7 Million
139,174 Added 99.18%
279,503 $29.1 Million
Q3 2020

Nov 08, 2023

SELL
$72.74 - $92.5 $15.8 Million - $20 Million
-216,546 Reduced 60.68%
140,329 $12 Million
Q3 2020

Nov 13, 2020

BUY
$72.74 - $92.5 $10.2 Million - $13 Million
140,329 New
140,329 $12 Million

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.